• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上皮性卵巢癌患者对基因检测的知识和态度。

The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.

机构信息

Center for Gynecologic Cancer, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Korea.

College of Nursing, Woosuk University, Wanju 55338, Korea.

出版信息

Int J Environ Res Public Health. 2021 Feb 26;18(5):2312. doi: 10.3390/ijerph18052312.

DOI:10.3390/ijerph18052312
PMID:33652933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7956717/
Abstract

This study assessed the knowledge and attitude of patients with ovarian cancer (OC) toward OC and next generation sequencing (NGS). The data, including characteristics of patients, their knowledge about OC and their knowledge and attitude of NGS, were collected from June to October 2018. Of the 103 participants, 70.9% ( = 73) had cancer within the second-degree relatives, and 18.4% ( = 19) had pathogenic mutations. The percentage of right answer for the knowledge about OC and NGS was 64.7% (11/17) and 50% (6/12), respectively. The median number of patients who had positive expectations for the genetic test was 34 (range, 22-44). Based on a first-degree familial history, patients had a different degree of knowledge about OC (11 vs. 8.5, = 0.026) and NGS (6.5 vs. 5, = 0.011), but patients with a pathogenic mutation did not have a different degree of knowledge about OC and NGS panel testing. High-income families had a more positive attitude towards the genetic test than low-income families ( = 0.005). Women with OC do not have enough knowledge about OC (11/17, 64.7%) and NGS (6/12, 50%) but they showed a positive attitude toward the NGS test. These women need OC and NGS educational intervention.

摘要

本研究评估了卵巢癌(OC)患者对 OC 和下一代测序(NGS)的知识和态度。这些数据包括患者的特征、他们对 OC 的了解以及他们对 NGS 的了解和态度,是在 2018 年 6 月至 10 月间收集的。在 103 名参与者中,70.9%(=73)的患者有二级亲属癌症史,18.4%(=19)有致病性突变。OC 和 NGS 知识的正确答案比例分别为 64.7%(11/17)和 50%(6/12)。对基因检测有积极期望的患者中位数为 34 人(范围 22-44)。根据一级家族病史,患者对 OC(11 与 8.5, = 0.026)和 NGS(6.5 与 5, = 0.011)的了解程度不同,但有致病性突变的患者对 OC 和 NGS 面板检测的了解程度没有差异。高收入家庭比低收入家庭对基因检测的态度更为积极( = 0.005)。OC 患者对 OC(11/17,64.7%)和 NGS(6/12,50%)的了解不足,但他们对 NGS 检测表现出积极态度。这些女性需要 OC 和 NGS 的教育干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3319/7956717/a2b11aecd92f/ijerph-18-02312-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3319/7956717/0e6c40d71086/ijerph-18-02312-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3319/7956717/a2b11aecd92f/ijerph-18-02312-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3319/7956717/0e6c40d71086/ijerph-18-02312-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3319/7956717/a2b11aecd92f/ijerph-18-02312-g002.jpg

相似文献

1
The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.上皮性卵巢癌患者对基因检测的知识和态度。
Int J Environ Res Public Health. 2021 Feb 26;18(5):2312. doi: 10.3390/ijerph18052312.
2
Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.选择卵巢癌患者进行胚系BRCA突变检测:指南及系统文献综述的结果
Adv Ther. 2016 Feb;33(2):129-50. doi: 10.1007/s12325-016-0281-1. Epub 2016 Jan 25.
3
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.卵巢癌中胚系和体细胞的同步测序:突变率及其对临床决策的影响。
Gynecol Oncol. 2020 Mar;156(3):517-522. doi: 10.1016/j.ygyno.2019.12.010. Epub 2019 Dec 27.
4
Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.卵巢癌患者BRCA基因检测建议的当前观点
Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4.
5
BRCA germline mutation test for all woman with ovarian cancer?对所有卵巢癌女性进行 BRCA 种系突变检测?
BMC Cancer. 2019 Jun 28;19(1):641. doi: 10.1186/s12885-019-5829-4.
6
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.对255例遗传性乳腺癌和卵巢癌女性病例系列进行多基因检测分析。
Oncotarget. 2017 Jul 18;8(29):47064-47075. doi: 10.18632/oncotarget.16791.
7
Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.土耳其特拉基亚地区高危 BRCA 相关乳腺癌/卵巢癌个体的遗传筛查结果。
J BUON. 2020 May-Jun;25(3):1337-1347.
8
The first Japanese nationwide multicenter study of mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of (CHARLOTTE).日本首个卵巢癌突变检测全国多中心研究:卵巢癌基因突变检测的横断面研究(CHARLOTTE)。
Int J Gynecol Cancer. 2019 Jul;29(6):1043-1049. doi: 10.1136/ijgc-2019-000384.
9
Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.特拉华州家族性胰腺癌的全州回顾性研究以及胰腺癌家族中基因突变的频率。
Ann Surg Oncol. 2016 May;23(5):1729-35. doi: 10.1245/s10434-015-5026-x. Epub 2016 Jan 4.
10
Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.使用下一代测序(NGS)平台从存档肿瘤标本中诊断致病性种系 BRCA1/2 突变。
Gynecol Oncol. 2019 Nov;155(2):275-279. doi: 10.1016/j.ygyno.2019.08.027. Epub 2019 Aug 31.

引用本文的文献

1
Exploring Literacy and Knowledge Gaps and Disparities in Genetics and Oncogenomics Among Cancer Patients and the General Population: A Scoping Review.探索癌症患者和普通人群在遗传学和肿瘤基因组学方面的读写能力、知识差距及差异:一项范围综述
Healthcare (Basel). 2025 Jan 9;13(2):121. doi: 10.3390/healthcare13020121.

本文引用的文献

1
Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?新诊断晚期卵巢癌的新辅助治疗:我们现状如何,又将走向何方?
Ann Transl Med. 2020 Dec;8(24):1710. doi: 10.21037/atm-20-1683.
2
Wise Management of Ovarian Cancer: On the Cutting Edge.卵巢癌的明智管理:处于前沿领域
J Pers Med. 2020 May 21;10(2):41. doi: 10.3390/jpm10020041.
3
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.多聚(ADP-核糖)聚合酶抑制剂:奥拉帕利在卵巢癌及其他领域的应用。
Drugs R D. 2020 Jun;20(2):55-73. doi: 10.1007/s40268-020-00301-8.
4
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
5
A scoping review of consumer needs for cancer information.消费者对癌症信息需求的范围综述。
Patient Educ Couns. 2019 Jul;102(7):1237-1250. doi: 10.1016/j.pec.2019.02.004. Epub 2019 Feb 8.
6
Cancer information-seeking preferences linked to distinct patient experiences and differential satisfaction with cancer care.癌症信息寻求偏好与患者独特的体验相关,并对癌症护理的满意度产生差异。
Patient Educ Couns. 2019 Jun;102(6):1187-1193. doi: 10.1016/j.pec.2019.01.009. Epub 2019 Jan 18.
7
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.奥拉帕利维持治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
8
Impact of a genetic counseling requirement prior to genetic testing.基因检测前进行遗传咨询要求的影响。
BMC Health Serv Res. 2018 Mar 7;18(1):165. doi: 10.1186/s12913-018-2957-5.
9
National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.有乳腺癌或卵巢癌病史女性的基因检测全国估计数。
J Clin Oncol. 2017 Dec 1;35(34):3800-3806. doi: 10.1200/JCO.2017.73.6314. Epub 2017 Aug 18.
10
Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.癌症遗传咨询与检测:上皮性卵巢癌患者及妇科肿瘤医疗服务提供者的观点
J Genet Couns. 2018 Feb;27(1):177-186. doi: 10.1007/s10897-017-0135-2. Epub 2017 Aug 7.